PATHOLOGICA最新文献_第8页

CIC-rearranged sarcoma presenting with superior vena cava syndrome: case report. 以上腔静脉综合征为表现的cic重排肉瘤1例。

IF 3.5

PATHOLOGICA Pub Date : 2023-04-01 DOI: 10.32074/1591-951X-784

Andrea Ascione, Giovanni Martino, Francesco Di Donato, Beatrice Casini, Renato Covello, Stefano Ascani

{"title":"CIC-rearranged sarcoma presenting with superior vena cava syndrome: case report.","authors":"Andrea Ascione, Giovanni Martino, Francesco Di Donato, Beatrice Casini, Renato Covello, Stefano Ascani","doi":"10.32074/1591-951X-784","DOIUrl":"https://doi.org/10.32074/1591-951X-784","url":null,"abstract":"CIC-rearranged sarcomas are rare mesenchymal neoplasms belonging to the family of undifferentiated small round cell sarcomas. This report details the case of a 45-year-old man presenting with symptoms of mediastinal compression, radiological diagnosis of a mediastinal mass and rapid evolution to full-blown superior vena cava syndrome. The emergency was successfully managed with a pharmacological approach. Formulation of a pathological diagnosis of CIC-rearranged sarcoma was initially supported by fluorescence in situ hybridisation findings and later validated by next-generation sequencing, which showed CIC-DUX4 gene fusion. A chemotherapy regimen was started with immediate benefits for the patient. The spectrum of pathological entities able to cause superior vena cava syndrome is wide, and recognition of rare causes is important to tailor the therapeutic approach to the specific disease. This is, to the best of our knowledge, the first report of CIC-rearranged sarcoma presenting with superior vena cava syndrome.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 2","pages":"97-100"},"PeriodicalIF":3.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/f2/pathol-2023-02-97.PMC10462994.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preoperative endoscopy and pathology report of the specimen to be recommended in sleeve gastrectomy? 术前内镜检查及标本病理报告推荐袖式胃切除术?

IF 3.5

PATHOLOGICA Pub Date : 2023-04-01 DOI: 10.32074/1591-951X-781

Remo Alessandris, Federico Moroso, Mauro Michelotto, Matteo Fassan, Valentina Angerilli, Linda Callegari, Mirto Foletto

{"title":"Preoperative endoscopy and pathology report of the specimen to be recommended in sleeve gastrectomy?","authors":"Remo Alessandris, Federico Moroso, Mauro Michelotto, Matteo Fassan, Valentina Angerilli, Linda Callegari, Mirto Foletto","doi":"10.32074/1591-951X-781","DOIUrl":"https://doi.org/10.32074/1591-951X-781","url":null,"abstract":"Objective: Preoperative upper gastrointestinal endoscopy (UGIE) and postoperative histopathological examination (HPE) of resected specimens are still controversial issues in bariatric surgery.Methods: A retrospective review of prospectively collected laparoscopic sleeve gastrectomies (SG) performed at our institution for morbid obesity was carried out. All patients underwent pre-operative UGIE with biopsy, post-operative HPE and conventional post-operative follow-up.Results: From January 2019 through January 2021 we performed a total of 501 laparoscopic SG. A total of 12 (2.4%) neoplasms were found, 2 evident at preoperative UGIE, 4 detected during operation, and 6 at HPE. Eight of these 12 cases had some malignant potential and 5 would not have been detected without HPE of the specimen. The most significant unexpected case was a fundic gland type adenocarcinoma in a 64-year-old female with severe obesity.Conclusion: On the basis of our clinical experience, we recommend both preoperative endoscopic assessment and postoperative HPE of the specimen to provide the best available treatment to these patients.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"115 2","pages":"90-96"},"PeriodicalIF":3.5,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/41/pathol-2023-02-90.PMC10463000.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10489408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Science and pseudo science: racist eugenics in Italy. 科学与伪科学:意大利的种族优生学。

IF 3.5

PATHOLOGICA Pub Date : 2023-04-01 DOI: 10.32074/1591-951X-844

Carlo Patriarca, Piergiorgio Modena, Maura Massimino, Fabio Gibilisco, Mattia Barbareschi, Andreas Conca

引用次数: 0

Brief history of the who blue books on urinary and male genital tumours. 世卫组织泌尿和男性生殖器肿瘤蓝皮书简史。

IF 3.5

PATHOLOGICA Pub Date : 2023-02-01 DOI: 10.32074/1591-951X-840

Ferran Algaba, Gabriella Nesi

引用次数: 0

Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome. 儿童型弥漫性低级别胶质瘤：在临床和生物学上与众不同的一组肿瘤，预后良好。

IF 4.4

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-828

Viscardo Paolo Fabbri, Chiara Caporalini, Sofia Asioli, Annamaria Buccoliero

引用次数: 0

Newly recognised Tumour Types in Glioneuronal tumours according to the 5th edition of the CNS WHO Classification. 根据CNS世界卫生组织分类第5版新发现的胶质神经元肿瘤类型。

IF 3.5

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-819

Valeria Barresi, Francesca Gianno, Gianluca Marucci

引用次数: 2

Ependymomas. Ependymes。

IF 3.5

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-817

Luca Bertero, Alessia Andrea Ricci, Cristian Tampieri, Paola Cassoni, Piergiorgio Modena

{"title":"Ependymomas.","authors":"Luca Bertero, Alessia Andrea Ricci, Cristian Tampieri, Paola Cassoni, Piergiorgio Modena","doi":"10.32074/1591-951X-817","DOIUrl":"https://doi.org/10.32074/1591-951X-817","url":null,"abstract":"Ependymal neoplasms are a heterogenous group of neoplasms arising from the progenitors of the cells lining the ventricular system and the spinal central canal. During the last few years, significant novel data concerning oncogenesis, molecular characteristics and clinical correlations of these tumours have been collected, with a strong relevance for their pathological classification. The recently published 5th edition of WHO Classification of Central Nervous System Tumours integrates this novel knowledge and represents a substantial update compared to the previous edition. Concerning supratentorial ependymomas, the previous RELA fusion-positive ependymoma has been renamed into ZFTA fusion-positive and the novel YAP1 fusion-positive ependymoma subtype has been added. Posterior fossa ependymomas should now be allocated either to the Type A or Type B subtypes based on molecular profiling or using the H3 K27me3 immunohistochemical surrogate. Regarding spinal ependymomas, a novel subtype has been added based on a distinctive molecular trait, presence of MYCN amplification, and on the unfavourable outcome. Finally, myxopapillary ependymoma is now classified as a grade 2 tumour in accordance with its overall prognosis which mirrors that of conventional spinal ependymomas. The aim of this review is to present these changes and summarize the current diagnostic framework of ependymal tumours, according to the most recent updates.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"436-446"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/2a/pathol-2022-06-436.PMC9763977.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Adult type diffuse gliomas in the new 2021 WHO Classification. 2021年WHO新分类中的成人型弥漫性胶质瘤

IF 3.5

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-823

Manila Antonelli, Pietro Luigi Poliani

{"title":"Adult type diffuse gliomas in the new 2021 WHO Classification.","authors":"Manila Antonelli, Pietro Luigi Poliani","doi":"10.32074/1591-951X-823","DOIUrl":"https://doi.org/10.32074/1591-951X-823","url":null,"abstract":"Adult-type diffuse gliomas represent a group of highly infiltrative central nervous system tumors with a prognosis that significantly varies depending on the specific subtype and histological grade. Traditionally, adult-type diffuse gliomas have been classified based on their morphological features with a great interobserver variability and discrepancy in patient survival even within the same histological grade. Over the last few decades, advances in molecular profiling have drastically changed the diagnostic approach and classification of brain tumors leading to the development of an integrated morphological and molecular classification endowed with a more clinically relevant value. These concepts were largely anticipated in the revised fourth-edition of WHO classification of central nervous system tumors published in 2016. The fifth-edition (WHO 2021) moved molecular diagnostics forward into a full integration of molecular parameters with the histological features into an integrative diagnostic approach. Diagnosis of adult type diffuse gliomas, IDH mutant and IDH-wildtype has been simplified by introducing revised diagnostic and grading criteria. In this review, we will discuss the most recent updates to the classification of adult-type diffuse gliomas and summarize the essential diagnostic keys providing a practical guidance to pathologists.","PeriodicalId":45893,"journal":{"name":"PATHOLOGICA","volume":"114 6","pages":"397-409"},"PeriodicalIF":3.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/41/pathol-2022-06-397.PMC9763975.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10479727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Expanding the spectrum of "mesenchymal" tumors of the central nervous system. 扩大了中枢神经系统“间质”肿瘤的范围。

IF 3.5

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-826

Cristina Pizzimenti, Francesca Gianno, Marco Gessi

引用次数: 2

Introduction. 介绍。

IF 3.5

PATHOLOGICA Pub Date : 2022-12-01 DOI: 10.32074/1591-951X-839

Mattia Barbareschi, Marco Gessi, Felice Giangaspero

引用次数: 0